$ALKS

snyderman nancy lynn MD sold $2.2M of ALKS

snyderman nancy lynn MD sold 44,472 shares of Alkermes plc. (ALKS) at $50.35 ($2.24M total) on 2026-08-03.

Original reporting
SEC EDGAR · snyderman nancy lynn MD
Published Aug 3, 2026, 11:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

A director open-market sale of $2.24M is disclosed, including trade date, share count, price, and remaining holdings; there is no accompanying operational or financial update.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a durable repricing without corroborating fundamental news.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still lacks context on taxes, personal liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-03 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for Alkermes plc.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

Alkermes director Nancy Lynn Snyderman sold 44,472 shares in an open-market transaction worth about $2.24M, filed on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction size, price, and post-sale holdings, but no accompanying company news or guidance change.

Market effects

No clear sector read-through from a single director sale without additional company or industry disclosures.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity or diversification and does not necessarily signal reduced confidence, especially without any other negative company-specific news.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider sale disclosure.

  • Nancy Lynn Snyderman, MD

    Director who sold 44,472 shares at $50.3480 per share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSMedAI 8/10

Phase 2 Data on Investigational Narcolepsy Drug Published

Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.

$ALKSMedAI 9/10

Did Positive Vibrance-1 Data and Brilliance Phase 3 Launch Just Shift Alkermes' (ALKS) Investment Narrative?

Alkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.

$ALKSMedAI 8/10

Alkermes plc: The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Alkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.